A Phase II Trial of TKI258 in Patients With Metastatic or Advanced Gastrointestinal Stromal Tumors (GIST) After Failure to Imatinib and Sunitinib(CTKI258AKR01T)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Dovitinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 13 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Jul 2013 Planned end date changed from 1 Mar 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
- 09 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.